Physician profile
Harold Lancer
NPI 1518131747
$3,341.41
in general payments reported to CMS, 2019-2025
13 companies · $304 in 2025
The $304 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $991 · 2020: $501 · 2021: $720 · 2022: $338 · 2023: $324 · 2024: $165 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $767 · Entertainment: $25.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $766.53 |
| Entertainment | $25.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $1,464.14 | 2019-2025 | Dysport |
| Sun Pharmaceutical Industries INC. | $519.01 | 2019-2025 | |
| Merz North America, INC. | $420.35 | 2019-2023 | |
| Leo Pharma INC. | $251.43 | 2019-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $241.32 | 2019-2020 | |
| Almirall LLC | $116.66 | 2019-2023 | Seysara |
| Pfizer INC. | $98.75 | 2019-2020 | |
| Janssen Biotech, INC. | $78.39 | 2022 | |
| Journey Medical Corporation | $74.51 | 2022-2025 | |
| Musculoskeletal Transplant Foundation INC. | $25.60 | 2025 | |
| Medimetriks Pharmaceuticals, INC. | $20.76 | 2022 | |
| Incyte Corporation | $17.69 | 2023 | Opzelura |
| Epi Health, LLC | $12.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harold Lancer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.